Different coagulation and fibrinolysis parameters were investigated in 149 patients with metastatic and non-metastatic tumours and results were compared with those obtained in a healthy population. Results showed a significant increase of thrombin-antithrombin complexes, fibrinopeptide A (FPA) and fibrin monomers in the group of patients (p< 0.001). There was also a significant prolongation of euglobulin lysis time (p< 0.005) and an increase of plasminogen activator inhibitor activity (p< O.OOOl), fibrinogen degradation products (p< O.OOl), and D-dimer (p< 0.05) in the group of patients as compared to controls: FPA levels were also increased in patients with metastases (p< 0.005). This study demonstrates clotting activation, at the level of fibrinogen to fibrin conversion, and impairment of fibrinolysis in patients with malignancy.
INTRODUCTION
The association of deep venous thrombosis with malignancy (Trousseau  syndrome) is poorly understood and but the underlying mechanisms responsible for alterations in the clotting system are far from being established (l-3). Tumours may release substances into the circulation that directly or indirectly activate the coagulation mechanism and contribute to No correlation was found between overall fibrinolytic activity and t-PA activity, nor between t-PA and PAI. 
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Sixty-five patients presented with metastases and 84 with local disease. The values of the coagulation and fibrinolysis parameters analyzed between patients with and without metastases is shown in Table I . Only the levels of FPA were significantly higher (p< 0.005) in patients with metastases as compared to those with local disease. 
DISCUSSION
Patients with malignancies show different alterations of the clotting and fibrinolytic systems. Although these abnormalities most often cause no symptoms, up to 10-15X of patients present clinically evident thrombosis, which is a common cause of death in hospitalized cancer patients (2, 19, 20) .
This study clearly demonstrates that activation of the coagulation system is common in patients with malignant disease. There was a significant increase of TAT complexes, FPA and fibrin monomers in the group of patients, suggesting thrombin generation followed by an increase of fibrinogen to fibrin conversion.
Generation of thrombin represents a central event within the coagulation cascade. Thrombin acts on different physiological substrates and is inhibited by antithrombin III, thereby forming an inactive proteinase/inhibitor complex (21, 22). Determination of the TAT complex may be important in the diagnosis of thrombosis. Patients with risk factors for thrombosis and disseminated intravascular coagulation are found to have increased levels of TAT (23, 24). An increase of TAT complexes in patients with malignancy has also been shown (25). 
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